Hugh Ronald Peter Reynolds
No más puestos en curso
Origen de la red de primer grado Hugh Ronald Peter Reynolds.
Entidad | Tipo de entidad | Industria | |
---|---|---|---|
Public Company | Miscellaneous Commercial Services | 15 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Hugh Ronald Peter Reynolds a través de su red personal
Empresa | Sector | Personas relacionadas | Puesto principal |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
CoTherix, Inc.
CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Pharmaceuticals: Major | Director/Board Member | |
PORTOLA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
Intradigm Corp.
Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Chairman Director/Board Member President Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
ANAPTYSBIO, INC. | Biotechnology | Chairman | |
E-THERAPEUTICS PLC | Biotechnology | Chairman Chief Operating Officer | |
Incline Therapeutics, Inc.
Incline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Incline Therapeutics, Inc. develops pharmaceutical products. The firm operates as hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system). The company was founded in 2009 and is headquartered in Seatle, WA. | Pharmaceuticals: Major | Founder | |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Director/Board Member | |
Stanford University | College/University | Corporate Officer/Principal Masters Business Admin Graduate Degree | |
University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
Atugen AG
Atugen AG Pharmaceuticals: MajorHealth Technology Atugen AG is a biopharmaceutical company. It develops RNAi therapeutics which focus on vivo applications in oncology and liver diseases, exploiting its proprietary oligonucleotide delivery technologies and chemically stabilized siRNA structures. Founded in 1998, the company is headquartered in Berlin, Germany | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
St. Jude Children's Research Hospital, Inc.
St. Jude Children's Research Hospital, Inc. Hospital/Nursing ManagementHealth Services St. Jude Children's Research Hospital, Inc. offers health care and social assistance services for children. It is internationally recognized for its pioneering research and treatment for children with cancer and other catastrophic diseases. The firm's treatment programs include brain tumors, leukemia, lymphoma, infectious diseases, immunodeficiency diseases, blood disorders, sickle cell disease, and solid tumors. The company was founded by Danny Thomas on February 4, 1962 and is headquartered in Memphis, TN. | Hospital/Nursing Management | Director/Board Member | |
University College London | College/University | Graduate Degree | |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | Pharmaceuticals: Major | Director/Board Member | |
Sérum International, Inc.
Sérum International, Inc. Wholesale DistributorsDistribution Services Sérum International, Inc. operates as online shoe store. It offers Birkenstock products as well as Tatami, Newalk, Papillio, Birki's, Birki kids, Birko, Birkenstock Comfort Shoes, FP by Birkenstock and Alpro lines. The company was founded in 1962 and is headquartered in Laval, Canada. | Wholesale Distributors | Director/Board Member | |
Autonomous University of Barcelona | College/University | Undergraduate Degree | |
The Institute of Directors (United Kingdom)
The Institute of Directors (United Kingdom) Miscellaneous Commercial ServicesCommercial Services The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA. | Pharmaceuticals: Other | Corporate Officer/Principal | |
Stanford University School of Medicine | College/University | Doctorate Degree | |
VENTURE LIFE GROUP PLC | Pharmaceuticals: Major | Founder | |
Kinnier Dufort Design Ltd. | Director/Board Member | ||
Kinnier Dufort Ltd. | Director/Board Member | ||
Avantis UK Ltd. | Director/Board Member | ||
Hootie Developments Ltd. | Director/Board Member | ||
Stratton Ventures Ltd. | Director/Board Member | ||
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
FHM Life Sciences VIII LLC | Corporate Officer/Principal | ||
Periproducts Ltd.
Periproducts Ltd. Medical SpecialtiesHealth Technology Periproducts Ltd. provides oral care products. Its product include Denti-Brush Interproximal, Wire-Free Interdental Brushes, and hyG Ionic toothbrush. The company is headquartered in Middlesex, the United Kingdom. | Medical Specialties | Director/Board Member | |
ALPINE IMMUNE SCIENCES, INC. | Biotechnology | Director/Board Member | |
MOLECULAR TEMPLATES, INC. | Biotechnology | General Counsel | |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Pharmaceuticals: Major | Director/Board Member | |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Director/Board Member | |
VIRPAX PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member | |
PHATHOM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Pharmaceuticals: Major | Director/Board Member | |
Lassen Therapeutics LLC
Lassen Therapeutics LLC Pharmaceuticals: MajorHealth Technology Lassen Therapeutics LLC operates as a therapeutic antibody company. It discovers and develops novel medicines to treat serious unmet medical needs. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Financial Conglomerates | Director/Board Member | |
Enlaza Therapeutics, Inc.
Enlaza Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and is building a pipeline of first-in-class covalent biologics. The CEO of the company is Sergio G. Duron. | Miscellaneous Commercial Services | Director/Board Member | |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Information Technology Services | Director/Board Member | |
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
ALLENA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member |
Estadísticas
Internacional
Estados Unidos | 35 |
Reino Unido | 13 |
Alemania | 2 |
Canadá | 2 |
España | 2 |
Sectorial
Health Technology | 33 |
Consumer Services | 6 |
Commercial Services | 3 |
Finance | 3 |
Health Services | 2 |
Operativa
Director/Board Member | 155 |
Chairman | 42 |
Corporate Officer/Principal | 42 |
Independent Dir/Board Member | 35 |
Chief Executive Officer | 21 |
Las relaciones más conectadas
Insiders | |
---|---|
Jeremy Curnock-Cook | 60 |
James Topper | 49 |
Iain Ross | 41 |
David Mack | 19 |
Barbara A. Ruskin | 12 |
Jeremy Randall | 10 |
Philip Haworth | 10 |
Annette Clancy | 10 |
Xiao Dong Yang | 9 |
Bernd O. Wetzel | 8 |
Eric James Boyle | 7 |
Michael Riley | 6 |
Laura Roca-Alonso | 6 |
Jeffery Scott Vick | 5 |
Iain N. H. Rugheimer | 1 |
- Bolsa de valores
- Insiders
- Hugh Ronald Peter Reynolds
- Conexiones Empresas